CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-01 | Kelsey Stephen Michael See Remarks | Grant or award | +36,600 | 296,345 | ||
| 2025-03-01 | Kelsey Stephen Michael See Remarks | Grant or award · Stock Option (Right to Buy) | +128,100 | 128,100 | ||
| 2025-03-01 | Horn Margaret A Chief Operating Officer | Grant or award | +28,600 | 156,591 | ||
| 2025-03-01 | Horn Margaret A Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +100,100 | 100,100 | ||
| 2025-03-01 | Wei Lin Chief Medical Officer | Grant or award | −20,800 | 91,651 | ||
| 2025-03-01 | Wei Lin Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +72,800 | 72,800 | ||
| 2025-03-01 | Wang Xiaolin See Remarks | Grant or award | +19,000 | 105,039 | ||
| 2025-03-01 | Wang Xiaolin See Remarks | Grant or award · Stock Option (Right to Buy) | +66,500 | 66,500 | ||
| 2025-03-01 | GOLDSMITH MARK A See Remarks | Grant or award | +97,400 | 453,302 | ||
| 2025-03-01 | GOLDSMITH MARK A See Remarks | Grant or award · Stock Option (Right to Buy) | +341,100 | 0 | ||
| 2025-01-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −2,406 | $40.50 | $97K | 39,222 |
| 2024-12-18 | GOLDSMITH MARK A See Remarks | Option exercise | +30,846 | $0.49 | $15K | 355,902 |
| 2024-12-18 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) | −30,846 | 0 | ||
| 2024-12-16 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −4,329 | $45.40 | $197K | 127,991 |
| 2024-12-16 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −11,714 | $45.40 | $532K | 325,056 |
| 2024-12-16 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −4,663 | $45.40 | $212K | 259,745 |
| 2024-12-16 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,599 | $45.40 | $73K | 41,628 |
| 2024-12-16 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −2,635 | $45.40 | $120K | 96,470 |
| 2024-12-05 | Schroeder Thilo Director | Purchase | +543,478 | $46.00 | $25.0M | 2,096,612 |
| 2024-12-05 | Schroeder Thilo Director | Purchase | +760,869 | $46.00 | $35.0M | 760,869 |
Page 19 of 29 · 569 trades